Takeda Pharmaceutical Company Limited

Good day, everyone, and welcome to the conference call of Takeda Pharmaceutical Company Limited. During the presentation from the company, all the telephone lines are placed for listening mode only, and a question and answer session will be held after the presentation. Now we start the conference. Mr. O'Reilly, please go ahead.

Hello, good morning, good afternoon, good evening. My name is Christopher O'Reilly, Global Head of Investor Relations. Thank you for joining this follow-up conference call on the fiscal 2020 financial results of Takeda Pharmaceutical Company Limited. Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20F and in our other SEC filings. Please also refer to the important notice on page two of the presentation materials. So let me introduce the panel for this session today. So we have Christoph Weber, our President and CEO, Andy Plump, President of R&D, Costa Sarucos, Chief Financial Officer, Ramona Sequeira, President of the U.S. Business Unit and Global Portfolio Commercialization, and Julie Kim, President of the Plasma-Derived Therapies Business Unit. So we're going to start with some opening remarks from Christoph and then a financial summary from Costa, after which we'll open up the lines for Q&A. If you have any questions, you can obviously ask over the call, or if you'd like to email your questions in, send it to someone from the Takeda IR team or to Takeda.ir.contact at Takeda.com. With that, I'll hand over to Christophe for some opening remarks.

Thank you, Chris. Hello, everyone. Thank you for taking the time to discuss with us our 2020 results and 2021 outlook. The 2020 results... We believe that demonstrated our resilience as an organization, but also as a business. We are delivering our management guidance. We are very pleased with the fact that we were able to deliver our synergy target to one year in advance. So that put us in a very good position in terms of margin and profitability and cash flow. We are closing the year 2020 with a 2.2% revenue growth on an underlying basis. And if you look at 2021, we are seeing this growth outlook to accelerate to a mid-single-digit underlying revenue growth, which is driven by our core businesses, our 14 global brands. So we do see this momentum. And we do describe... uh as a 2021 year as an inflection year not only for our business again because we have we have delivered our synergies our our growth is accelerating but because also about the because of the pipeline and we do expect the year 2021 to be a very special year in terms of the pipeline maturity and the pipeline progression so in a nutshell that's where we are it's a it's an inflection year for for us and we are looking forward to discussing it with you. Thank you.